.Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX12_Viltolarsen.Viltolarsen .Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX12_Viltolarsen.Viltolarsen| name: | Viltolarsen | |
| ATC code: | M09AX12 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 80 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 0.17 | L/h/kg |
| other parameters in model implementation | ||
Viltolarsen is an antisense oligonucleotide drug designed to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation amenable to exon 53 skipping. It is administered intravenously and was approved by the FDA in August 2020 for this indication.
Pharmacokinetics in ambulatory pediatric male patients (ages 4 to <10 years) with Duchenne muscular dystrophy after single and multiple intravenous infusions.